Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Withdrawn

A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain

Outcome
Stopped earlyThe study was never initiated by sponsor. Patients where never recruited. (Enrollment)
Phase
No phase (not a drug trial)
Status
Withdrawn
Study type
Interventional
Planned start
April 2016
Planned end
September 2018
Enrollment
0 participants
Sites
1
Primary outcomes
Visual Analog Scale Pain Scores
Sponsor type
Industry
Results posted
No
Last update
15 February 2019

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to compare efficacy of pain treatment with ITDD to efficacy of pain treatment with CMM in patients with pancreatic cancer pain.

Detailed description public domain (ClinicalTrials.gov)

This study is a non-randomized, open-label, single-center study that will compare efficacy of pain treatment with ITDD to efficacy of pain treatment with CMM in patients suffering from pancreatic cancer pain. There will be two treatment groups: Study group (ITDD): These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain. Systemic analgesics will not be prescribed for this group. Control group (CMM): These subjects will be treated with CMM to treat their pain. A maximum of 30 subjects (maximum of 15 in each treatment group) may be enrolled in this study at one study center.